Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma

Fig. 2

Response and outcomes. a Representative PET-CT image of a CR patient before and after induction treatment. b Percentage decline of metabolic tumor volume (MTV) during the induction treatment in 21 patients with available PET-CT evaluation. The decline in MTV was measured with interim evaluation of PET-CT in 4 of 22 cases (marked with an asterisk), 3 patients discontinued the treatment, and another withdrew after interim evaluation. The decline in MTV could not be measured in 1 case, who discontinued the treatment before interim evaluation. c Dynamical documentation of circulating EBV DNA copies during induction treatment in responders and non-responders. d Kaplan-Meier plot showing PFS and OS. The numbers of patients who could be evaluated for each endpoint are shown. Tick marks indicate censored data. e Kaplan-Meier plot showing PFS and OS of responders and non-responders in the chemo-free cohort. P values in (c) were compared between responders and non-responders using student’s t test. P values in (e) were compared between responders and non-responders using log-rank test

Back to article page